Danny Hsu and Nicola Pozzi on “Tetra-Positive” APS
Danny Hsu, President of THANZ, reposted from Nicola Pozzi on LinkedIn:
”Are we overlooking the “Tetra-Positive” APS patient?
Lupus Anticoagulant (LAC) remains our most valuable predictor of thrombosis, yet it is plagued by analytical interference and false positives.
A compelling new Historical Sketch in JTH by Prof Vittorio Pengo and A/Prof Nicola Pozzi argues it is time to embrace antiprothrombin antibodies to resolve these diagnostic dilemmas.
Key Takeaways for the Lab and Clinic:
- The Rise of “Tetra-Positivity”: Patients positive for LAC, aCL, anti-β2GPI, and aPS/PT (anti-phosphatidylserine/prothrombin) represent a distinct, high-risk phenotype with persistent antibody profiles.
The LAC Surrogate: When LAC results are compromised by acute phase reactants or anticoagulants (heparin/DOACs), aPS/PT testing offers a critical safety net. If aCL, anti-β2GPI, and aPS/PT are all positive, consider the patient high-risk even without a confirmed LAC.
Mechanism Matters (Type I vs. Type II): Not all antibodies are equal. Prothrombin exists in “open” and “closed” forms.
– Type I Antibodies: Recognize the open form (cryptic epitopes). They show weak LAC activity.
– Type II Antibodies: Recognize both forms. These are the drivers of strong LAC activity.
The Future: Keep an eye on aPT-Bio, a new assay using biotinylated recombinant prothrombin that retains native structure, potentially offering higher specificity than current ELISAs.
It is time to refine our risk stratification beyond the standard ‘Triple Positive.”’
Quoting Nicola Pozzi‘s post:
”Hematologists and coagulation enthusiasts—this one’s for you!
Lupus anticoagulant: What is it? How do we measure it?
Why does it matter for Antiphospholipid Syndrome (APS)?
Vittorio Pengo and I revisit this highly debated topic with a historical perspective, and share novel mechanistic insights we uncovered in recent years that could reshape how we understand and test for lupus anticoagulant.
Could it be time to rewrite the coagulation textbook?
Time (and good science) will tell…”
Read the full article in JTH.
Article: Lupus anticoagulant and antiprothrombin antibodies: embracing the future
Authors: Vittorio Pengo, Nicola Pozzi
Stay updated on all scientific advances with Hemostasis Today.
-
Feb 26, 2026, 15:58Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
-
Feb 26, 2026, 15:51Augustina Isioma Ikusemoro: The Real Miracle in Trauma Care Happens Behind the Scenes
-
Feb 26, 2026, 15:42Jim Hoffman։ Targeting NETosis to Improve Perfusion and Reduce Thrombosis in AMI
-
Feb 26, 2026, 15:40Elvira Grandone: ISTH Launches An International Survey to Capture Real-World Practice of Pregnancy Anemia
-
Feb 26, 2026, 15:39Ashok Yadav: Placental Glycogen as a Vital Energy Reserve for Fetal and Placental Health
-
Feb 26, 2026, 15:37Nayab Ahmed: Main Reasons for Washing Platelet-Rich Plasma
-
Feb 26, 2026, 15:36Robert Negrin Shares His Outlook for the Year Ahead as ASH President
-
Feb 26, 2026, 15:24Nancy Shapiro: Excited to See This Publication on Current Landscape of Anticoagulation Stewardship Released
-
Feb 26, 2026, 15:15Ahmed Nasreldein: Stay Current on Key Updates in Ischemic and Hemorrhagic Stroke